Stimulation of bone resorption results in a selective increase in the growth rate of spontaneously metastatic Walker 256 cancer cells in bone.
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
To test the hypothesis that bone metastasis is related to the rate of bone remodeling, we have examined the effect of enhanced bone resorption on the growth of spontaneously metastatic Walker 256 (W256) cancer cells. Bone resorption was stimulated in male Fischer rats by injecting Rice H-500 Leydig tumor cells subcutaneously. The resorptive response of the skeleton was confirmed in a pilot study by evaluating parameters of bone morphometry after 4, 7 and 10 days of tumor burden. The distal femoral epiphyses had 35 +/- 10% more osteoclast surface, 83 +/- 11% less osteoblast surface, and 46 +/- 5% less trabecular bone after 10 days of tumor burden, compared to non-tumor-bearing controls. To evaluate the effect of Leydig tumor-induced bone resorption on the growth response of W256 cells, 20 rats were injected intramuscularly with 2 x 10(7) W256 cells, and 20 rats were vehicle-injected. Two days later, 10 rats from each group were injected subcutaneously with Leydig tumor cells. Twelve days after W256/vehicle injection, rats were injected with [3H]thymidine, killed 2 h later, and their femurs, liver, lungs and kidneys were processed for histology. In rats injected with Leydig tumor cells only, enhanced bone resorption was confirmed by a 40 +/- 4% increase in serum calcium concentration, a 48 +/- 8% decrease in trabecular bone content, and a 72 +/- 15% decrease in osteoblast surface, compared with non-tumor-bearing rats. Metastatic W256 cells adjacent to trabecular bone in Leydig tumor-bearing rats had a 56 +/- 18% greater relative [3H]thymidine labeling index (TdR) than did W256 cells in the bones of non-Leydig tumor-bearing rats. The TdRs of W256 cells in the liver, lungs, and kidneys were not affected by Leydig tumor burden. In this model, enhanced bone resorption was associated with the selective growth promotion of metastatic W256 cells in bone, suggesting the existence of a bone-derived factor which is mitogenic to W256 cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stimulation of bone resorption was shown to specifically increase the proliferation rate of metastatic cancer cells in bone, but not in other tissues (303).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [303]
Citations
Cites
A METHOD FOR THE RAPID DETERMINATION OF ALKALINE PHOSPHATASE WITH FIVE CUBIC MILLIMETERS OF SERUM
Bessey, O. A., Lowry, O. H., & Brock, M. J. (1946) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)43072-4 · Cited by 3,046
NEW YORK STATE JOURNAL OF MEDICINE.
(1901) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1901.02470020041007 · Cited by 1,472
Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro.
Robey, P. G., Young, M. F., Flanders, K. C., Roche, N. S., Kondaiah, P., Reddi, A. H., Termine, J. D., Sporn, M. B., & Roberts, A. B. (1987) · The Journal of cell biology · doi:10.1083/jcb.105.1.457 · Cited by 557 · cited 1×
“TGF-fl is a component of organic bone matrix [30], and is synthesized and secreted by osteoblasts [ 31 ].”
BackgroundNicolson, G. L. (1988) · CANCER AND METASTASIS REVIEW · doi:10.1007/bf00046483 · Cited by 502 · cited 1×
“Human malignancies often have distinct, predictable patterns of hematogenous spread which are independent of the first capillary bed encountered [ 4 ].”
BackgroundPowell, G. J., Southby, J., Danks, J. A., Stillwell, R. G., Hayman, J., Henderson, M. A., Bennett, R. C., & Martin, T. J. (1991) · PubMed · Cited by 445
Use of P-Nitrophenylphosphate as the Substrate in Determination of Serum Acid Phosphatase*
Andersch, M. A., & Szczypinski, A. J. (1947) · American Journal of Clinical Pathology · doi:10.1093/ajcp/17.7_ts.571 · Cited by 318
Yates, A. J., Gutierrez, G. E., Smolens, P., Travis, P. S., Katz, M. S., Aufdemorte, T. B., Boyce, B. F., Hymer, T. K., Poser, J. W., & Mundy, G. R. (1988) · Journal of Clinical Investigation · doi:10.1172/jci113406 · Cited by 268 · cited 1×
“These effects on the skeleton have recently been attributed to the production and secretion by Leydig tumor cells of parathyroid hormone-related protein (PTHrP) [20, 21], a polypeptide which has been shown to cause similar systemic skeletal responses when directly injected into rats [ 22 , 23].”
BackgroundTechniques in Cell Cycle Analysis
(1987) · Humana Press eBooks · doi:10.1007/978-1-60327-406-7 · Cited by 159
Nicolson, G. L., & Dulski, K. M. (1986) · International Journal of Cancer · doi:10.1002/ijc.2910380221 · Cited by 143 · cited 1×
“been shown to be influenced by the environment within the tissues that they colonize [ 1-3 ].”
BackgroundFinkelman, R. D., Linkhart, T. A., Mohan, S., Lau, K. H., Baylink, D. J., & Bell, N. H. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.9.3657 · Cited by 105 · cited 1×
“TGF-fl is a component of organic bone matrix [ 30 ], and is synthesized and secreted by osteoblasts [31].”
BackgroundPhysiology of Blood Circulation of Bone
Shim, S. S. (1968) · Journal of Bone and Joint Surgery · doi:10.2106/00004623-196850040-00018 · Cited by 102
Proceedings of the First Workshop on Bone Morphometry.
(1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-86-5-684_5 · Cited by 97
Mechanism of malignant hypercalcaemia in carcinoma of the breast.
Percival, R. C., Yates, A. J. P., Gray, R. E., Galloway, J., Rogers, K., Neal, F. E., & Kanis, J. A. (1985) · BMJ · doi:10.1136/bmj.291.6498.776 · Cited by 96 · cited 1×
“with osteolysis and hypercalcemia [5, 6 ]. While the skeleton is rarely the exclusive target of metastatic cells, the extent and frequency of its involvement would not be predicted by its modest blood supply, estimated at 5-10% of cardiac output [7].”
BackgroundInsogna, K. L., Stewart, A. F., Vignery, A., Weir, E. C., NAMNUM, P. A., Baron, R., Kirkwood, J. M., DEFTOS, L. M., & Broadus, A. E. (1984) · Endocrinology · doi:10.1210/endo-114-3-888 · Cited by 89 · cited 3×
“The effects of 13-19 days of tumor burden have been reported to include increased osteoclast number or activity [15-18], decreased formation surface [15, 16, 18], decreased trabecular bone content [15, 17, 18], and hypercalcemia [15, 16 , 18, 19].”
BackgroundRevell, P. A. (1986) · Springer eBooks · doi:10.1007/978-1-4471-1377-5 · Cited by 65
Martodam, R. R., Thornton, K. S., Sica, D. A., D'Souza, S. M., Flora, L., & Mundy, G. R. (1983) · Calcified Tissue International · doi:10.1007/bf02405086 · Cited by 61 · cited 4×
“The effects of 13-19 days of tumor burden have been reported to include increased osteoclast number or activity [15-18], decreased formation surface [15, 16, 18], decreased trabecular bone content [15, 17, 18], and hypercalcemia [15, 16, 18 , 19].”
BackgroundInfluentialKrempien, B., Wingen, F.-J., Eichmann, T., Müller, M., & Schmähl, D. (2009) · Oncology · doi:10.1159/000226528 · Cited by 58
Naito, S., Giavazzi, R., & Fidler, I. J. (1987) · PubMed · Cited by 54
Growth regulation of cancer metastases by their host organ.
Sargent, N. S. E., Oestreicher, M., Haidvogl, H., Madnick, H. M., & Burger, M. M. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.19.7251 · Cited by 51 · cited 1×
“been shown to be influenced by the environment within the tissues that they colonize [ 1-3 ].”
BackgroundA morphological and phenotypic analysis of Walker 256 cells.
Simpkins, H., Lehman, J. M., Mazurkiewicz, J. E., & Davis, B. H. (1991) · PubMed · Cited by 48
Kitazawa, R., Imai, Y., Fukase, M., & Fujita, T. (1991) · Bone and Mineral · doi:10.1016/0169-6009(91)90029-y · Cited by 48 · cited 1×
“These effects on the skeleton have recently been attributed to the production and secretion by Leydig tumor cells of parathyroid hormone-related protein (PTHrP) [20, 21], a polypeptide which has been shown to cause similar systemic skeletal responses when directly injected into rats [22, 23 ].”
BackgroundThe hypercalcemic rat leydig cell tumor—A model of the humoral hypercalcemia of malignancy
Sica, D. A., Martodam, R. R., Aronow, J., & Mundy, G. R. (1983) · Calcified Tissue International · doi:10.1007/bf02405048 · Cited by 40 · cited 2×
“The effects of 13-19 days of tumor burden have been reported to include increased osteoclast number or activity [ 15-18 ], decreased formation surface [15, 16, 18], decreased trabecular bone content [15, 17, 18], and hypercalcemia [15, 16, 18, 19].”
BackgroundWoodruff, M. (1990) · Oxford University Press eBooks · doi:10.1093/oso/9780198542544.003.0005 · Cited by 40
Insogna, K. L., Weir, E. C., WU, T. L., Stewart, A. F., Broadus, A. E., & Burtis, W. J. (1987) · Endocrinology · doi:10.1210/endo-120-5-2183 · Cited by 35 · cited 1×
“These effects on the skeleton have recently been attributed to the production and secretion by Leydig tumor cells of parathyroid hormone-related protein (PTHrP) [ 20 , 21], a polypeptide which has been shown to cause similar systemic skeletal responses when directly injected into rats [22, 23].”
BackgroundHenderson, J. E., Bernier, S. M., D'AMOUR, P., & Goltzman, D. (1990) · Endocrinology · doi:10.1210/endo-127-3-1310 · Cited by 32 · cited 1×
“These effects on the skeleton have recently been attributed to the production and secretion by Leydig tumor cells of parathyroid hormone-related protein (PTHrP) [20, 21 ], a polypeptide which has been shown to cause similar systemic skeletal responses when directly injected into rats [22, 23].”
BackgroundKostenuik, P. J., Singh, G., Suyama, K. L., & Orr, F. W. (1992) · Clinical & Experimental Metastasis · doi:10.1007/bf00133469 · Cited by 29
Self-citationOrr, F. W., Millar-Book, W., & Singh, G. (1990) · PubMed · Cited by 29
Self-citationMetastatic carcinoma in association with Paget's disease of bone
Powell, N. (1983) · British Journal of Radiology · doi:10.1259/0007-1285-56-668-582 · Cited by 23 · cited 1×
“For example, in patients with known malignancy who present with Paget's disease, a disorder of increased bone remodeling, it has been reported that the Pagetic lesions are often the first sites of skeletal metastasis [ 8 , 9]. Such observations have suggested the hypothesis that the rate of bone remodeling regulates t…”
BackgroundPaget's disease. Coexistence with metastatic carcinoma.
Fp, A., Norman, A., Hirschl, S., & Klein, R. (1976) · PubMed · Cited by 22
Quantitative Methods in Bone Biopsy Examination
Revell, P. A. (1986) · Springer eBooks · doi:10.1007/978-1-4471-1377-5_4 · Cited by 19
Berger, M. E., Golub, M. S., Sowers, J. R., Brickman, A. S., Nyby, M. D., Troyer, H., Rude, R. K., Singer, F. R., Horst, R. L., & Deftos, L. J. (1982) · Life Sciences · doi:10.1016/0024-3205(82)90237-5 · Cited by 17 · cited 1×
“The effects of 13-19 days of tumor burden have been reported to include increased osteoclast number or activity [15-18], decreased formation surface [15, 16, 18], decreased trabecular bone content [15, 17, 18], and hypercalcemia [15, 16, 18, 19 ].”
BackgroundBani, M. R., & Giavazzi, R. (2003) · Humana Press eBooks · doi:10.1385/1-59259-222-8:297 · Cited by 17
Rayner, D. C., Orr, F. W., & Shiu, R. P. C. (1985) · PubMed · Cited by 13
Self-citationSkeletal response in rats following the implantation of hypercalcemia-producing Leydig cell tumors
Tam, C. S., Heersche, J. N. M., Santora, A. C., & Spiegel, A. M. (1984) · Metabolism · doi:10.1016/0026-0495(84)90161-6 · Cited by 13 · cited 4×
“The effects of 13-19 days of tumor burden have been reported to include increased osteoclast number or activity [15-18], decreased formation surface [15, 16, 18], decreased trabecular bone content [ 15 , 17, 18], and hypercalcemia [15, 16, 18, 19].”
BackgroundInfluentialAutoradiographic Techniques for Measurement of the Labeling Index
Simpson‐Herren, L. (1987) · Humana Press eBooks · doi:10.1007/978-1-60327-406-7_1 · Cited by 13 · cited 1×
“The percentage of labeled cells in each metastatic site was divided by the percentage of labeled cells in the same animars primary tumor to obtain a relative thymidine labeling index (TdR) [ 27 ].”
SCHARLA, S. H., Minne, H. W., Lempert, U. G., Krieg, P., Rappel, S., Maurer, E., Grohe, U., & Ziegler, R. (1991) · Hormone and Metabolic Research · doi:10.1055/s-2007-1003615 · Cited by 12
Millar-Book, W., Orr, F. W., & Singh, G. (1990) · Clinical & Experimental Metastasis · doi:10.1007/bf00135873 · Cited by 12
Self-citation
Research works printed but not linked: 1
- Easty GC and Carter RL. Patterns and mechanisms of bone destruction by skeletal metastases. In: Symington T and Carter RL, eds. Oncology Supplement: Scientific Foundation of Oncology. London: William Heinemann Medical Books, 1980.
Cited by
Kearns, A. E., Khosla, S., & Kostenuik, P. J. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0014 · Cited by 824
Self-citationBisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro.
van der Pluijm, G., Vloedgraven, H., van Beek, E., van der Wee-Pals, L., Löwik, C., & Papapoulos, S. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118841 · Cited by 305
Morony, S., Capparelli, C., Sarosi, I., Lacey, D. L., Dunstan, C. R., & Kostenuik, P. J. (2001) · PubMed · Cited by 318
Self-citationZoledronic Acid Inhibits Visceral Metastases in the 4T1/luc Mouse Breast Cancer Model
Hiraga, T., Williams, P. J., Ueda, A., Tamura, D., & Yoneda, T. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0325 · Cited by 242
Hiraga, T., Williams, P. J., Mundy, G. R., & Yoneda, T. (2001) · PubMed · Cited by 256
Metadata
- Authors
- Kostenuik, P. J., Singh, G., Suyama, K. L., & Orr, F. W.
- Affiliations
- McMaster University (CA)
- Venue
- Clinical & Experimental Metastasis
- Published
- 1992-11
- Volume
- 10
- Issue
- 6
- Pages
- 411-418
- ISSN
- 0262-0898 (ISSN-L)
- 1573-7276
- OpenAlex
- W2048584238
- Cited by
- 34
- References
- 37
- Citations by year
- 2019: 1 · 2016: 1 · 2013: 1
- FWCI
- 0.13
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Clinical & Experimental Metastasis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Management of metastatic bone disease
- Keywords
- bone metastasis, bone resorption, bone remodeling, Walker 256 carcinosarcoma, osteoclasts, osteoblasts, trabecular bone, tumor cell proliferation, bone morphometry, serum calcium
- MeSH terms
- Animals, Body Burden, Bone Neoplasms, Bone Resorption, Calcium, Carcinoma 256, Walker, Cell Division, Leydig Cell Tumor, Male, Neoplasm Transplantation, Pilot Projects, Rats, Inbred F344, Testicular Neoplasms, Thymidine, Tritium, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.